Back

Select your region

Schedule a cord blood consultation

Make an appointment

Stem Cells
Therapies

Stem Cells Therapies

The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).

FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.

Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.

Check the full list of patients who received stem cell therapy derived from FamiCord labs.

List last update: 06.2026

List of patients who received stem cells from FamiCord Group laboratories

List of patients who received stem cells from FamiCord Group laboratories
Lp. Source Source type Diagnosis Medical field Year of application Therapy Country Age of recipient
1001 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 65
1002 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 61
1003 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 65
1004 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 19
1005 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
1006 Apheresis Allogeneic Mixed Phenotype Acute Leukemia Hematology 2025 Standard Therapy Poland 47
1007 Apheresis Allogeneic Polycythemia Vera Hematology 2025 Standard Therapy Poland 61
1008 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 56
1009 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 53
1010 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 55
1011 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Poland 34
1012 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 50
1013 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy Poland 71
1014 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy Poland 64
1015 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 54
1016 Apheresis Autologous Non-Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 50
1017 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 50
1018 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 35
1019 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 54
1020 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
1021 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
1022 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 55
1023 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 64
1024 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 68
1025 Apheresis Allogeneic Primary myelofibrosis Hematology 2025 Standard Therapy Germany 71
1026 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 47
1027 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 58
1028 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 68
1029 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 44
1030 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 59
1031 Apheresis Autologous Lymphoma Non-Hodgkin Hematology 2025 Standard Therapy Portugal 58
1032 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 59
1033 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 2
1034 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 41
1035 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy France 48
1036 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 64
1037 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy United Kingdom 63
1038 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 64
1039 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1040 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Poland 68
1041 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Germany 59
1042 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 56
1043 Apheresis Allogeneic Diffuse Large B-cell Lymphoma Hematology 2025 Standard Therapy Belarus 53
1044 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 60
1045 Apheresis Allogeneic Immunodeficiency – LRBA Hematology 2025 Standard Therapy Turkey 14
1046 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 20
1047 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 65
1048 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 54
1049 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 75
1050 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1051 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 48
1052 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 37
1053 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Chile 40
1054 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1055 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Switzerland 65
1056 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Portugal 68
1057 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Estonia 9
1058 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 63
1059 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 67
1060 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 45
1061 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 59
1062 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 69
1063 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 64
1064 Apheresis Allogeneic Acute lymphoblastic leukemia Hematology 2025 Standard Therapy Germany 42
1065 Apheresis Autologous Primary central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
1066 Apheresis Allogeneic Myelodysplastic Syndrome/ Acute Myeloid Leukemia Hematology 2025 Standard Therapy Germany 62
1067 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 42
1068 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 55
1069 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 72
1070 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 58
1071 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 65
1072 Apheresis Autologous Follicular lymphoma Hematology 2025 Standard Therapy Germany 67
1073 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1074 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 60
1075 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 64
1076 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 63
1077 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 67
1078 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 60
1079 Apheresis Autologous Hodgkin lymphoma rezidiv Hematology 2025 Standard Therapy Germany 65
1080 Apheresis Autologous Non-Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 64
1081 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 67
1082 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1083 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1084 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1085 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 66
1086 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1087 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 60
1088 Apheresis Allogeneic Fanconi’s Anemia Hematology 2025 Standard Therapy Ukraine 6
1089 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 69
1090 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
1091 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Macedonia 56
1092 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy CROATIA 64
1093 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 75
1094 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy NETHERLANDS 65
1095 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
1096 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Brazil 48
1097 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 17
1098 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy United Kingdom 13
1099 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 69
1100 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 13